Progression of secreted frizzled-related protein family in cancer

doi:10.3760/cma.j.issn.1673-422X.2016.06.013

Abstract

Abstract: Secreted frizzledrelated protein (SFRP) can inhibit the expression of Wnt signaling pathway through Frizzled protein. The silencing of SFRP gene promoter methylation is associated with the occurrence and metastasis of many cancers such as colorectal cancer, gastric cancer, liver carcinoma, lung cancer and ovarian cancer. Several studies have found that SFRP gene has latent clinical value, which is expected to become the novel target for the gene diagnosis and treatment of cancer.

Key words: Signal transduction, Targeted gene repair, Neoplasms, Secreted frizzled-related protein

Li Lihong, Bai Zhongtian, Hu Jinjing, Zhou Wence. Progression of secreted frizzled-related protein family in cancer[J]. Journal of International Oncology, 2016, 43(6): 448-451.

References

［1］ Surana R, Sikka S, Cai W, et al. Secreted frizzled related proteins: implications in cancers［J］. Biochim Biophys Acta, 2014, 1845(1): 53-65. DOI: 10.1016/j.bbcan.2013.11.004. ［2］ Lavergne E, Hendaoui I, Coulouarn C, et al. Blocking Wnt signaling by SFRPlike molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active βcatenin［J］. Oncogene, 2011, 30(4): 423-433. DOI: 10.1038/onc.2010.432. ［3］ Kobayashi NC, Noronha SM. Cancer stem cells: a new approach to tumor development［J］. Rev Assoc Med Bras, 2015, 61(1): 86-93. DOI: 10.1590/1806-9282.61.01.086. ［4］ Arya M, Thrasivoulou C, Henrique R, et al. Targets of Wnt/βcatenin transcription in penile carcinoma［J］. PLoS One, 2015, 10(4): e0124395. DOI: 10.1371/joural.pone.0124395. ［5］ Cruciat CM, Niehrs C. Secreted and transmembrane wnt inhibitors and activators［J］. Cold Spring Harb Perspect Biol, 2013, 5(3): a015081. DOI: 10.1101/cshperspect.a015081. ［6］ Lavergne E, Hendaoui I, Coulouarn C, et al. Blocking Wnt signaling by SFRPlike molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active βcatenin［J］. Oncogene, 2011, 30(4): 423-433. DOI: 10.1038/onc.2010.432. ［7］ Liu JB, Zhang YX, Zhou SH, et al. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis［J］. World J Gastroenterol, 2011, 17(42): 4718-4724. DOI: 10.3748/wjg.v17.i42.4718. ［8］ Esteve P, Sandonìs A, Ibaez C, et al. Secreted frizzledrelated proteins are required for Wnt/βcatenin signalling activation in the vertebrate optic cup［J］. Development, 2011, 138(19): 4179-4184. DOI: 10.1242/dev.065839. ［9］ Peng C, Xiao XQ, Kang B, et al. Serum secreted frizzledrelated protein 5 levels differentially decrease in patients with hepatitis B virusassociated chronic infection and hepatocellular carcinoma［J］. Oncol Lett, 2014, 8(3): 1340-1344. DOI: 10.3892/ol.2014.2256 ［10］ Ding SL, Yang ZW, Wang J, et al. Integrative analysis of aberrant Wnt signaling in hepatitis B virusrelated hepatocellular carcinoma［J］. World J Gastroenterol, 2015, 21(20): 6317-6328. DOI: 10.3748/wjg.v21.i20.6317. ［11］卫波, 陈斌, 成扬, 等. 乙型肝炎病毒X蛋白调控sFRP1和sFRP5启动子区的甲基化修饰及其分子机制的探讨［J］. 中国病原生物学杂志, 2014, 9(6): 504-508. DOI:10.13350/j.cjpb.140607. ［12］欧玉荣, 景桂英, 刘娟, 等. Wnt信号通路T细胞因子4、βcatenin与SFRP1在结直肠癌中表达及预后关系［J］. 生物医学工程学杂志, 2015, 32(4): 854-861. DOI: 10.7507/1001-5515.20150153. ［13］贾凤洁, 孙冬生, 徐龙健, 等. 粪便中SFRP2基因甲基化与大肠癌的相关性［J］. 中国老年学杂志, 2015, 35(5): 1206-1208. ［14］杜美林, 王小玲, 樊建平, 等. 胃癌及癌前病变中幽门螺杆菌感染与分泌型卷曲相关蛋白基因启动子甲基化的关系研究［J］. 中国全科医学, 2013, 16(12C): 4272-4275. DOI: 10.3961/j.issn.1007-9572.2013.12.078. ［15］ Liu JB, Wu XM, Cai J, et al. CpG island methylator phenotype and Helicobacter pylori infection associated with gastric cancer［J］. World J Gastroenterol, 2012, 18(36): 5129-5134. DOI: 10.3748/wjg.v18.i36.5129. ［16］李明, 刘振平. 胃癌组织中Fascin和SFRP1的表达及相互关系［J］. 黑龙江医药科学, 2014, 37(6): 97-98. ［17］宋毓飞, 张谢, 孙蓓蕾, 等. 联合检测血浆SFRP2、RNF180基因甲基化在胃癌临床诊断中的价值［J］. 胃肠病学, 2015, 20(1): 19-23. DOI: 10.3969/j.issn.1008-7125.2015.01.006. ［18］ Bu XM, Zhao CH, Zhang N, et al. Hypermethylation and aberrant expression of secreted frizzledrelated protein genes in pancreatic cancer［J］. World J Gastroenterol, 2008, 14(21): 3421-3424. DOI: 10.3748/wjg.14.3421. ［19］ Perry AS, O′Hurley G, Raheem OA, et al. Gene expression and epigenetic discovery screen revealmethylation of SFRP2 in prostate cancer［J］. Int J Cancer, 2013, 132 (8): 1771-1780. DOI: 10.1002/ijc.27798. ［20］ MartinManso G, Calzada MJ, Chuman Y, et al. sFRP-1 binds via its netrinrelated motif to the Nmodule of thrombospondin1 and blocks thrombospondin1 stimulation of MDAMB231 breast carcinoma cell adhesion and migration［J］. Arch Biochem Biophys, 2011, 509(2): 147-156. DOI: 10.1016/j.abb.2011.03.004. ［21］ Ghoshal A, Ghosh SS. Expression, purification, and therapeutic implications of recombinant sFRP1［J］. Appl Biochem Biotechnol, 2015, 175(4): 2087-2103. DOI: 10.1007/s12010-014-1354-8.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.